AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic muscle-wasting disease caused by failure to produce dystrophin. The orphan drug designation potentially may provide AVI up to 10 years of market exclusivity if the drug candidate is approved for marketing in the European Union (EU)…

View post: 
AVI BioPharma’s Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy

You may also like:

• Anthrax Alert For Heroin Users In London
• FDA Issues Guidance To Help Streamline Medical Device Clinical Trials
• NHS Stroke Improvements Have Saved Lives
• Early Biomarker Of Insulin Resistance And Glucose Intolerance Identified In A Nondiabetic Population
• AVI BioPharma’s Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
• Possible ‘Artificial Pancreas’ For Children With Diabetes
• FDA Issues Guidance To Help Streamline Medical Device Clinical Trials
• LFB’s Recombinant Anti-CD20 Monoclonal Antibody Is Granted Orphan Drug Status In Europe For Chronic Lymphocytic Leukemia
• CHMP Recommends ‘Januvia(R)’(sitagliptin), From MSD, For Restricted First Line Use In European Union
• GSK Receives CHMP Positive Opinion For A New Indication For Arixtra